MILLER K C , CHINTAKUNTLAWAR A V . Molecular-driven therapy in advanced thyroid cancer [J ] . Curr Treat Options Oncol , 2021 , 22 ( 3 ): 24 . DOI: 10.1007/s11864-021-00822-7 http://doi.org/10.1007/s11864-021-00822-7

中国临床肿瘤学会CSCO甲状腺癌专家委员会 . 碘难治性分化型甲状腺癌靶向药物不良反应管理专家共识(2018年版) [J ] . 中国癌症杂志 , 2018 , 28 ( 7 ): 545 - 553 . DOI: 10.19401/j.cnki.1007-3639.2018.07.012 http://doi.org/10.19401/j.cnki.1007-3639.2018.07.012

Thyroid Cancer Committee of Chinese Society of Clinical Oncology . Expert consensus on adverse drug reactions management of iodine refractory differentiated thyroid cancer (2018 edition) [J ] . China Oncol , 2018 , 28 ( 7 ): 545 - 553 .

U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [EB/OL ] . ( 2017-11-27 )[ 2023-06-30 ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

KOMMALAPATI A , TELLA S H , BORAD M , et al . FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice [J ] . Cancers (Basel) , 2021 , 13 ( 12 ): 2968 . DOI: 10.3390/cancers13122968 http://doi.org/10.3390/cancers13122968 https://www.mdpi.com/2072-6694/13/12/2968 https://www.mdpi.com/2072-6694/13/12/2968

Centre for Evidence-Based Medicine . Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) [EB/OL ] . ( 2009-03-01 )[ 2023-06-30 ] . https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009.

FINK A , KOSECOFF J , CHASSIN M , et al . Consensus methods: characteristics and guidelines for use [J ] . Am J Public Health , 1984 , 74 ( 9 ): 979 - 983 . DOI: 10.2105/ajph.74.9.979 http://doi.org/10.2105/ajph.74.9.979

BROSE M S , NUTTING C M , JARZAB B , et al . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J ] . Lancet , 2014 , 384 ( 9940 ): 319 - 328 . DOI: 10.1016/S0140-6736(14)60421-9 http://doi.org/10.1016/S0140-6736(14)60421-9

ZHENG X Q , XU Z G , JI Q H , et al . A randomized, phase Ⅲ study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer [J ] . Clin Cancer Res , 2021 , 27 ( 20 ): 5502 - 5509 . DOI: 10.1158/1078-0432.CCR-21-0761 http://doi.org/10.1158/1078-0432.CCR-21-0761 https://aacrjournals.org/clincancerres/article/27/20/5502/671674/A-Randomized-Phase-III-Study-of-Lenvatinib-in https://aacrjournals.org/clincancerres/article/27/20/5502/671674/A-Randomized-Phase-III-Study-of-Lenvatinib-in

LIN Y , YANG H , SHI F , et al . Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, placebo-controlled, multi-center phase Ⅲ clinical trial (DIRECTION) [J ] . Ann Oncol , 2022 , 33 ( Suppl_7 ): S1294 .

CHI Y , ZHENG X Q , ZHANG Y , et al . Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase Ⅱ trial [J ] . Clin Cancer Res , 2023 : CCR-C22 - 3406 .

LI D P , CHI Y , CHEN X H , et al . Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial [J ] . Clin Cancer Res , 2021 , 27 ( 13 ): 3567 - 3575 . DOI: 10.1158/1078-0432.CCR-20-2950 http://doi.org/10.1158/1078-0432.CCR-20-2950 https://aacrjournals.org/clincancerres/article/27/13/3567/671471/Anlotinib-in-Locally-Advanced-or-Metastatic https://aacrjournals.org/clincancerres/article/27/13/3567/671471/Anlotinib-in-Locally-Advanced-or-Metastatic

OBA T , CHINO T , SOMA A , et al . Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis [J ] . Endocr J , 2020 , 67 ( 12 ): 1215 - 1226 . DOI: 10.1507/endocrj.EJ20-0171 http://doi.org/10.1507/endocrj.EJ20-0171 https://www.jstage.jst.go.jp/article/endocrj/67/12/67_EJ20-0171/_article https://www.jstage.jst.go.jp/article/endocrj/67/12/67_EJ20-0171/_article

LI L Y , CHENG L , SA R , et al . Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers [J ] . Crit Rev Oncol Hematol , 2022 , 172 : 103624 . DOI: 10.1016/j.critrevonc.2022.103624 http://doi.org/10.1016/j.critrevonc.2022.103624 https://linkinghub.elsevier.com/retrieve/pii/S1040842822000488 https://linkinghub.elsevier.com/retrieve/pii/S1040842822000488

U.S. Food and Drug Administration . FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation [EB/OL ] . ( 2022-06-23 )[ 2023-06-30 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unre sectable-or-metastatic-solid.

SUBBIAH V , KREITMAN R J , WAINBERG Z A , et al . Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study [J ] . Ann Oncol , 2022 , 33 ( 4 ): 406 - 415 . DOI: 10.1016/j.annonc.2021.12.014 http://doi.org/10.1016/j.annonc.2021.12.014 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059

BUSAIDY N L , KONDA B , WEI L , et al . Dabrafenib versus dabrafenib+trametinib in BRAF -mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial [J ] . Thyroid , 2022 , 32 ( 10 ): 1184 - 1192 .

GAO M , ZHENG X , WANG Y , et al . Efficacy and safety of pralsetinib, a selective RET inhibitor, in Chinese patients with advanced RET -mutant medullary thyroid cancer [C ] . Thyroid , 2021 , 31 ( Suppl_1 ): abstract LBO 3.

ZHENG X Q , JI Q H , SUN Y P , et al . Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase Ⅱ LIBRETTO-321 study [J ] . Ther Adv Med Oncol , 2022 , 14 : 17588359221119318.

CABANILLAS M E , LIN J J , BROSE M S , et al . Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC) [J ] . J Clin Oncol , 2023 , 41 ( Suppl_16 ): 6091 . DOI: 10.1200/JCO.2023.41.16_suppl.6091 http://doi.org/10.1200/JCO.2023.41.16_suppl.6091 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.6091 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.6091

KRZAKOWSKI M J , LU S , COUSIN S , et al . Updated analysis of the efficacy and safety o f entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive ( NTRK -fp) solid tumors [J ] . J Clin Oncol , 2022 , 40 ( Suppl_16 ): 3099 .

DOEBELE R C , DRILON A , PAZ-ARES L , et al . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [J ] . Lancet Oncol , 2020 , 21 ( 2 ): 271 - 282 . DOI: S1470-2045(19)30691-6 http://doi.org/S1470-2045(19)30691-6

REED N , GLEN H , GERRARD G , et al . Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer [J ] . Clin Oncol (R Coll Radiol) , 2020 , 32 ( 5 ): e145 - e153 . DOI: 10.1016/j.clon.2019.11.010 http://doi.org/10.1016/j.clon.2019.11.010

LYON A R , LÓPEZ-FERNÁNDEZ T , COUCH L S , et al . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [J ] . Eur Heart J , 2022 , 43 ( 41 ): 4229 - 4361 . DOI: 10.1093/eurheartj/ehac244 http://doi.org/10.1093/eurheartj/ehac244

MCLELLAN B , CIARDIELLO F , LACOUTURE M E , et al . Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management [J ] . Ann Oncol , 2015 , 26 ( 10 ): 2017 - 2026 . DOI: 10.1093/annonc/mdv244 http://doi.org/10.1093/annonc/mdv244

REN Z G , ZHU K S , KANG H Y , et al . Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma [J ] . J Clin Oncol , 2015 , 33 ( 8 ): 894 - 900 . DOI: 10.1200/JCO.2013.52.9651 http://doi.org/10.1200/JCO.2013.52.9651

WORDEN F , FASSNACHT M , SHI Y K , et al . Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer [J ] . Endocr Relat Cancer , 2015 , 22 ( 6 ): 877 - 887 . DOI: 10.1530/ERC-15-0252 http://doi.org/10.1530/ERC-15-0252 https://erc.bioscientifica.com/view/journals/erc/22/6/877.xml https://erc.bioscientifica.com/view/journals/erc/22/6/877.xml

HADDAD R I , SCHLUMBERGER M , WIRTH L J , et al . Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes [J ] . Endocrine , 2017 , 56 ( 1 ): 121 - 128 . DOI: 10.1007/s12020-017-1233-5 http://doi.org/10.1007/s12020-017-1233-5

KIYOTA N , SCHLUMBERGER M , MURO K , et al . Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer [J ] . Cancer Sci , 2015 , 106 ( 12 ): 1714 - 1721 . DOI: 10.1111/cas.2015.106.issue-12 http://doi.org/10.1111/cas.2015.106.issue-12 https://onlinelibrary.wiley.com/toc/13497006/106/12 https://onlinelibrary.wiley.com/toc/13497006/106/12

SCHLUMBERGER M , TAHARA M , WIRTH L J , et al . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer [J ] . N Engl J Med , 2015 , 372 ( 7 ): 621 - 630 . DOI: 10.1056/NEJMoa1406470 http://doi.org/10.1056/NEJMoa1406470 http://www.nejm.org/doi/10.1056/NEJMoa1406470 http://www.nejm.org/doi/10.1056/NEJMoa1406470

NERVO A , RETTA F , RAGNI A , et al . Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update [J ] . Crit Rev Oncol Hematol , 2021 , 168 : 103533 . DOI: 10.1016/j.critrevonc.2021.103533 http://doi.org/10.1016/j.critrevonc.2021.103533 https://linkinghub.elsevier.com/retrieve/pii/S1040842821003206 https://linkinghub.elsevier.com/retrieve/pii/S1040842821003206

SCHADENDORF D , ROBERT C , DUMMER R , et al . Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF -mutant cancers [J ] . Eur J Cancer , 2021 , 153 : 234 - 241 . DOI: 10.1016/j.ejca.2021.05.005 http://doi.org/10.1016/j.ejca.2021.05.005 https://linkinghub.elsevier.com/retrieve/pii/S0959804921003038 https://linkinghub.elsevier.com/retrieve/pii/S0959804921003038

ATKINSON V , LONG G V , MENZIES A M , et al . Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists [J ] . Asia Pac J Clin Oncol , 2016 , 12 ( Suppl 7 ): 5 - 12 .

ATKINSON V , ROBERT C , GROB J J , et al . Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: primary results of COMBI-APlus [J ] . Eur J Cancer , 2022 , 163 : 79 - 87 . DOI: 10.1016/j.ejca.2021.12.015 http://doi.org/10.1016/j.ejca.2021.12.015

SUBBIAH V , HU M I , WIRTH L J , et al . Pralsetinib for patients with advanced or metastatic RET -altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study [J ] . Lancet Diabetes Endocrinol , 2021 , 9 ( 8 ): 491 - 501 . DOI: 10.1016/S2213-8587(21)00120-0 http://doi.org/10.1016/S2213-8587(21)00120-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200

YIMAER W , ABUDOUYIMU A , TIAN Y , et al . Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials [J ] . Onco Targets Ther , 2016 , 9 : 1167 - 1173 .